Dr Kathryn Zeitz will replace Kylie Ward, bringing some needed stability to the college.
Dr Kathryn Zeitz, current deputy CEO of the Central Adelaide Local Health Network, has been named as the new CEO of the Australian College of Nursing.
Dr Zeitz replaces Kylie Ward who was sacked as CEO in May after allegations of “potential financial irregularities”.
The announcement was made at the ACN National Nursing Forum (NNF) in Cairns.
Dr Zeitz has led the clinical governance portfolio at CALHN since 2019. CALHN is South Australia’s largest network, incorporating the Royal Adelaide Hospital and The Queen Elizabeth Hospital.
Upon graduation from Flinders University, she started her nursing career in Accident and Emergency at Flinders Medical Centre in Adelaide.
Her extensive acute hospital operational management background has included many roles within CALHN and at St Vincent’s Health Network in Sydney. She successfully completed her PhD thesis in clinical nursing at the University of Adelaide in 2003.
She has contributed to nearly 50 peer-reviewed publications from her research interests, which include mass gathering medicine, acute hospital capacity management, and patient-centred care.
Dr Zeitz is an Adjunct Associate Professor with Flinders University and an Adjunct Professor at The University of Adelaide.
Since 2017, she has been a nursing representative on the Independent Hospital Pricing Authority Clinical Advisory Committee. She has previously been the chair of Variety SA and a board director for Variety Australia, for which she was awarded Life Membership in 2021.
She is a long-standing volunteer and leader within St John Ambulance Australia, where she is currently a board director.
Dr Zeitz is a fellow of CRANAplus, the peak professional body for remote health, and was a board director from 2011-2017.
She has been a member of the Australian College of Nursing for over 30 years.
Dr Zeitz will start her new role at ACN in late September 2024.
New non-exec director for CSL
CSL Limited has appointed Elaine Sorg as an independent non-executive director, effective 1 September.
CSL’s Chair, Dr Brian McNamee AO said:
“We are pleased to welcome Elaine to CSL’s Board of Directors. She is a well-respected global leader in the biopharmaceutical industry, with a track record of successfully building franchises and brands across therapeutic areas and segments.
“Her expertise will be a strong complement to our board’s existing skillset and be vital as CSL continues to execute on its growth ambitions.”
Ms Sorg has more than 35 years’ experience as a senior executive with leading pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was senior vice president for AbbVie and president of AbbVie’s US commercial operations, the company’s largest commercial business. She was a key leader in bringing a number of groundbreaking medicines to patients across immunology, oncology, neuroscience and eye care.
Ms Sorg is currently on the Dean’s advisory council at Purdue University School of Pharmacy and Pharmaceutical Science, and is a senior advisor at the Boston Consulting Group, where she advises global healthcare clients on business-critical strategies and decisions.
Northern Queensland PHN on the hunt
NQPHN is seeking expressions of interest to fill the position of the independent nominations and remuneration committee chair from 28 November. The position is becoming vacant due to the current Chair advising of his retirement at the November 2024 AGM.
The PHN is also looking to fill three upcoming vacancies on its board. Three directors are retiring by rotation, and two of those directors are eligible to reapply.
For more information contact companysecretary@nqphn.com.au no later than close of business on 9 September.